(8NBNG169) A Thesis on “TO STUDY PROMOTIONAL STRATEGY ADOPTED BY RANBAXY LABORATORIES LTD RELATED TO RANITIDINE-150mg (Antiulcerant) IN NAGPUR CITY” INTRODUCTION OBJECTIVES:- To study the overview of Indian Pharmaceutical Market. To study the culture of Ranbaxy Lab. To find out the promotional strategies used by Ranbaxy with respect to ‘Histac’ tab. To find out various promotional strategies used by Ranbaxy to acquire market share in Nagpur city. To study the competitors of
Premium Generic drug Pharmaceutical industry Gastroesophageal reflux disease
Ranbaxy Laboratories Limited (Ranbaxy) is a research based international pharmaceutical company serving customers in over 150 countries. The company was incorporated in 1961 and it went public in 1973.In 1998 Ranbaxy entered the United States which is the largest pharmaceutical market. In 2008 Daiichi Sankyo a leading pharmaceutical innovator‚ headquartered in Tokyo‚ Japan acquired a controlling share in the company. Ranbaxy produces a wide range
Premium Generic drug Pharmaceutical industry Ranbaxy Laboratories
Metrics Used to Measure Training Impact At Ranbaxy L.N.D. Report Compiled By: Group 5 Aditi Chahana Nayan Prasun Priyam Under the Guidance of Prof. A. U. Bhaskar Acknowledgement All of us together have put in constant efforts in the making of this report. However‚ it would not have been successful without the kind support‚ help and guidance of all our mentors. We would like to extend our sincere thanks to all of them without which this would not have been possible. We are
Premium Ranbaxy Laboratories Skill Donald Kirkpatrick
Limited’s (Ranbaxy) profile as a pharmaceutical company underwent a sea change during the period 1985-1995. During this period Ranbaxy diversified into different products‚ markets and in general over the ‘value curve’. Its export sales grew from 7.45% of total sales in 1985 to 42.4% of total sales 1995. The growth in the foreign markets was primarily led by bulk drugs and intermediates‚ which constituted 80% of the foreign sales in 1995. Driven by the vision of CEO Parvinder Singh‚ Ranbaxy had consciously
Free Developed country Developing country Emerging markets
| Ranbaxy Laboratories Ltd. | | "Personally‚ I feel that companies who constantly innovate to provide better products and services and who can offer superior value propositions to the consumer are the ones likely to command more respect globally than others” Malvinder Mohan Singh‚ former CEO and MD‚ Ranbaxy Laboratories Ltd Table of Contents Executive Summary 5 The Company 5 Hybrid Business Model 6 Porter’s Five Force Analysis 7 Bargaining Power of Buyers 8 Bargaining
Premium Generic drug Pharmaceutical industry Ranbaxy Laboratories
Ranbaxy – Daiichi Sankyo Deal Akash Bangani Dipika Bhura Gaurav Khetan Neetu Rathod 12065 12077 12082 12118 Agenda • • • • • • • • • • Industry Overview Companies’ Profiles Snapshot of the deal Financing the deal Benefits to Daiichi Benefits to Ranbaxy Synergies Post Acquisition challenges Recent Developments Conclusion Indian Pharmaceutical Industry • Present size of $14 billion. • Ranks 4th in world in terms of production and 13th in terms of consumption. • Highly fragmented. 325 large
Premium Generic drug Pharmaceutical industry 3rd millennium
9 9.1 9.2 10 11 Title Introduction Background of Ranbaxy Brief History Market share of Ranbaxy Background of Daiichi Sankyo Brief History Market share of Daiichi Sankyo SPOT Analysis of the Indian Pharma Industry Resaons for the Deal Why Ranbaxy did it Why Daiichi Sankyo did it Disadvantages of the deal The Deal Shareholding Pattern Interpretation of the Shareholding pattern Financing the Deal Effects of the Acquisition Benefits for Ranbaxy Benefits for Daiichi Sankyo Benefits for the combined
Premium Pharmaceutical industry Generic drug
Ranbaxy Laboratories Ltd. (RLL) is the largest pharmaceutical company incorporated in India. It is also amongst the top league globally and is ranked 9th largest generic company worldwide. Ranbaxy is also credited with the tag of true Indian multinational. The company traces its roots to a chemist shop in Delhi. It is one of the first Indian pharmaceutical company to start a joint venture abroad. Rapid growth of Ranbaxy is attributed mainly to its focused research and joint ventures in India and
Premium Generic drug Marketing Ranbaxy Laboratories
in the global healthcare arena and Ranbaxy endeavors to be at the forefront in delivering the India centric advantages to the advanced and developing countries of the world. From a small domestic company at inception‚ Ranbaxy has grown formidably to be a Billion dollar institution that was envisioned by Late Dr Parvinder Singh‚ Chairman and Managing Director‚ Ranbaxy in early 90’s. It is with the unwavering ’ dedication ’ and the ’ will to win ’ of Team Ranbaxy across the globe that it has traversed
Premium Human resource management
Summary This case explores the possibility of a brand extension for Revital‚ the bestselling vitamin and mineral supplement and number-one nutraceutical brand in India and a top Ranbaxy Global Consumer Healthcare product. The case examines Revital’s shift from a prescription product to a popular over-the-counter (OTC) brand and explores Ranbaxy’s strategies to position Revital as the brand with the highest recall. It assesses Revital’s competitors in India’s booming nutraceutical market in a scenario
Free Target market Marketing Caffeine